Previous 10 | Next 10 |
MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will par...
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung Disease MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for ...
Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients Treatment-Refractory MAC Lung Disease Clinical Development Strategy to Focus Initially on Japan and U.S., Two Countries with Highest Preval...
AN2 Therapeutics ( NASDAQ: ANTX ) has secured a contract valued up to $17.8M from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of epetraborole for acute systemic melioidosis. The award...
Non-dilutive funding will drive synergies with existing epetraborole development program for NTM lung disease Award leverages AN2 Therapeutics expertise and commitment to address urgent unmet global health needs Work could help address U.S. biothreat pathogen MENLO PARK,...
MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, President and C...
AN2 Therapeutics press release ( NASDAQ: ANTX ): Q2 GAAP EPS of -$0.53 beats by $1.36 . Cash, cash equivalents and investments totaled $115.8 million on June 30, 2022. The Company expects that current cash, cash equivalents and investments, including net proceeds ...
Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023 Completed Enrollment in Phase 1 PK/Safety Study of Epetraborole in Healthy Volun...
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung disease Phase 2/3 pivotal trial expected to support regulatory approv...
Gainers: AN2 Therapeutics (ANTX) +7%. Design Therapeutics (DSGN) +6%. Edgio (EGIO) +5%. Humacyte (HUMA) +5%. Rhythm Pharmaceuticals (RYTM) +5%. Losers: Swvl Holdings (SWVL) -10%. Amedisys (AMED) -8%. Lilium (LILM) -5%. Centessa Pharmaceuticals (CNTA) -5%. KLX Energy Services Holding...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...